In anti-tumor therapy, PD-L1 is already a key player in personalized medicine, since it represents a druggable target (Sun et al. 2018; Honda et al. 2017; Kataoka and Ogawa 2016; Kataoka et al. 2016; Isaacsson Velho and Antonarakis 2018; Fan et al. 2019). This evidence concerns the gene CD274 and neoplasm.